Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,651 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G. Schellhammer P, et al. Among authors: jones j. Urology. 1995 May;45(5):745-52. doi: 10.1016/s0090-4295(99)80077-6. Urology. 1995. PMID: 7538237 Clinical Trial.
Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G. Schellhammer P, et al. Among authors: jones j. Urology. 1996 Jan;47(1A Suppl):54-60; discussion 80-4. doi: 10.1016/s0090-4295(96)80010-0. Urology. 1996. PMID: 8560679 Clinical Trial.
A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G. Soloway MS, et al. Among authors: jones j. Eur Urol. 1996;29 Suppl 2:105-9. doi: 10.1159/000473848. Eur Urol. 1996. PMID: 8717471 Clinical Trial.
Multicenter evaluation of an investigational prostate cancer methylation assay.
Baden J, Green G, Painter J, Curtin K, Markiewicz J, Jones J, Astacio T, Canning S, Quijano J, Guinto W, Leibovich BC, Nelson JB, Vargo J, Wang Y, Wuxiong C. Baden J, et al. Among authors: jones j. J Urol. 2009 Sep;182(3):1186-93. doi: 10.1016/j.juro.2009.05.003. Epub 2009 Jul 21. J Urol. 2009. PMID: 19625061 Clinical Trial.
Editorial Commentary.
Jones JS. Jones JS. Urol Pract. 2020 Jan;7(1):27. doi: 10.1097/01.UPJ.0000613556.73535.1c. Epub 2019 Nov 8. Urol Pract. 2020. PMID: 37317364 No abstract available.
Editorial Commentary.
Jones JS. Jones JS. Urol Pract. 2020 May;7(3):203-204. doi: 10.1097/UPJ.0000000000000083.01. Epub 2020 Jan 23. Urol Pract. 2020. PMID: 37317426 No abstract available.
14,651 results
You have reached the last available page of results. Please see the User Guide for more information.